NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SECRETARIES AND/OR AMINO ACID SEQUENCE DISCLOSURES
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.823 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:note attached sample statement for CRF
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact: [무
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support (SIRA) Technical Assistance
To Purchase Patentin Soπware

Application No.: 09/625,469

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPORSE

AUG 0 5 2002 IN THE UNITED STATES F

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 94,784-L)

In application o	f:)
	T.)

Stojiljkovic *et al*.

) Before the Examiner:) R. Hayes

Serial No.

09/665,358

Group Art Unit: 1647

Filed:

September 19, 2000

For:

Növel Bacterial Hemoglobin Receptor

Genes and Uses

TRANSMITTAL LETTER

Commissioner for Patents Washington, D.C. 20231

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached

Request to Use Computer Readable Form from Another Application and return postcard

- 2. No additional fee is required.
- 3. Please charge any additional fees or credit overpayment to Deposit Account No. **13-2490**. A duplicate copy of this sheet is enclosed.
- 4. CERTIFICATE UNDER 37 CFR 1.10: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 herein above, are being sent via U.S. Postal Service as "Express Mail" in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 5th day of August 2002.

By:

kevin E. Noonan, Ph.D.

No. 35,303